When mice lack BAP31 and drink alcohol, their liver cells leak more enzymes into the blood, showing they’re more damaged.
Scientific Claim
BAP31 deficiency in mice is associated with a 23.2% higher serum ALT and 31.4% higher serum AST after ethanol exposure compared to wild-type mice, indicating significantly worsened hepatocellular injury.
Original Statement
“Following ethanol exposure, BAP31-LKO mice exhibited elevated serum alanine transaminase (23.2%, p < 0.05) and aspartate transaminase (31.4%, p < 0.05) levels compared to WT mice.”
Evidence Quality Assessment
Claim Status
appropriately stated
Study Design Support
Design supports claim
Appropriate Language Strength
association
Can only show association/correlation
Assessment Explanation
The study shows a clear, statistically significant association between BAP31 deficiency and elevated liver enzymes after ethanol in mice. Causation cannot be proven without intervention, so 'associated with' is appropriate.
Gold Standard Evidence Needed
According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.
Randomized Controlled TrialLevel 1bWhether restoring BAP31 function reduces serum ALT/AST in ethanol-exposed BAP31-deficient mice.
Whether restoring BAP31 function reduces serum ALT/AST in ethanol-exposed BAP31-deficient mice.
What This Would Prove
Whether restoring BAP31 function reduces serum ALT/AST in ethanol-exposed BAP31-deficient mice.
Ideal Study Design
A double-blind RCT in 40 BAP31-LKO mice, randomized to receive hepatocyte-specific BAP31 gene therapy or control vector, followed by 6 g/kg ethanol; primary outcomes are serum ALT and AST at 24h, with secondary outcomes of liver histology and survival.
Limitation: Cannot be translated directly to humans due to gene therapy complexity and ethical barriers.
Prospective Cohort StudyLevel 2bWhether low hepatic BAP31 expression in humans predicts higher ALT/AST in chronic alcohol users.
Whether low hepatic BAP31 expression in humans predicts higher ALT/AST in chronic alcohol users.
What This Would Prove
Whether low hepatic BAP31 expression in humans predicts higher ALT/AST in chronic alcohol users.
Ideal Study Design
Prospective cohort of 300 chronic heavy drinkers (≥60g ethanol/day for >5 years), measuring BAP31 protein levels in liver biopsies and correlating with serum ALT/AST levels over 12 months, adjusting for BMI, viral hepatitis, and alcohol use patterns.
Limitation: Cannot prove BAP31 loss causes elevated enzymes—only that they co-occur.
In Vitro StudyLevel 5In EvidenceWhether BAP31 knockdown increases hepatocyte death and LDH release under ethanol exposure.
Whether BAP31 knockdown increases hepatocyte death and LDH release under ethanol exposure.
What This Would Prove
Whether BAP31 knockdown increases hepatocyte death and LDH release under ethanol exposure.
Ideal Study Design
Primary human hepatocytes from 20 donors, transfected with BAP31 siRNA or control, treated with 100 mM ethanol for 24h, measuring LDH release, caspase-3 activation, and cell viability via flow cytometry, with 3 biological replicates.
Limitation: Does not reflect systemic inflammation or immune-mediated injury in vivo.
Evidence from Studies
Supporting (1)
Scientists removed a protein called BAP31 from mice and gave them alcohol. The mice without BAP31 had much higher levels of liver damage markers than normal mice, proving that lacking this protein makes alcohol hurt the liver more.